• search hit 6 of 6
Back to Result List

The art of virtualizing pharma R&D

  • Today, virtualizing pharma R&D is increasingly related with data analytics and artificial intelligence (AI), technologies that have been developed by software companies outside the healthcare sector. The process of virtualizing pharma R&D is closely related to the technological advancements that result in the generation of large data sets ranging from genomics, proteomics, metabolomics, medical imaging, IoT wearables and large clinical trials, making it necessary for pharma companies to find new ways to store and ultimately analyze information. As a consequence, pharma companies are experimenting with AI in R&D ranging from in-silico drug design to clinical trail participants identification or dosage error reduction.

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Name:Schuhmacher, Alexander
DOI:https://doi.org/10.1016/j.drudis.2019.07.004
Erschienen in:Drug discovery today
Publisher:Elsevier
Place of publication:Amsterdam
Document Type:Article
Language:English
Year of Publication:2019
Volume:24
Issue:11
Pagenumber:3
First Page:2105
Last Page:2107
Dewey Decimal Classification:610 Medizin, Gesundheit
Open Access:Nein